Beovu (brolucizumab-dbll) is a brand-name drug prescribed for certain eye conditions in adults. Beovu comes as a liquid solution that’s given by an eye doctor. The typical dosage is one dose given ...
The intravitreal (eyeball) injection drug Beovu hasn’t even been on the market for two years, but its history has been eventful. This medication was meant to help patients with an eye problem known as ...
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic ...
Beovu (brolucizumab-dbll) can cause side effects that range from mild to serious. More common side effects include blurry vision and cataract. If side effects from Beovu become difficult to tolerate, ...
ZURICH (Reuters) - Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly ...
The Food and Drug Administration (FDA) has approved Beovu (brolucizumab-dbll; Novartis) injection, also referred to as RTH258, for the treatment of neovascular (wet) age-related macular degeneration ...
Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns. ZURICH, Feb 25 (Reuters) - Novartis ...
Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk when it comes to prescribing the medicine. The American ...
SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results